Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company focused on investigational therapies for neurodegenerative and endocrine diseases, and its news flow reflects the progress and setbacks typical of clinical-stage drug development. Company updates frequently highlight milestones in its pipeline, including avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis (ALS), and AMX0318 as a long-acting GLP-1 receptor antagonist candidate.
Investors following AMLX news can expect regular announcements on clinical trial progress, such as enrollment status, early safety and tolerability data, and biomarker analyses from studies like the Phase 3 LUCIDITY trial in PBH and the Phase 1 LUMINA trial in ALS. Amylyx also issues press releases when it reports financial results, providing context on research and development spending, cash runway, and the anticipated timing of key clinical and regulatory milestones.
Another recurring news theme is regulatory and program updates, including FDA designations, decisions to advance or discontinue specific programs, and detailed descriptions of conditions such as PBH, ALS, PSP, and Wolfram syndrome. The company has, for example, communicated its decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results, while continuing development of AMX0035 in Wolfram syndrome.
Amylyx also announces capital markets events and investor outreach, such as underwritten public offerings of common stock and participation in healthcare and biopharma conferences. For readers tracking AMLX, this news page offers a consolidated view of clinical, financial, and strategic disclosures that shape the company’s development trajectory. Bookmarking this feed can help investors and observers monitor how Amylyx’ investigational therapies advance through trials and how management communicates key developments.
Amylyx Pharmaceuticals (Nasdaq: AMLX) has announced its participation in three upcoming investor conferences in New York City:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 1:50pm ET
- Baird 2024 Global Healthcare Conference on September 10, 2024, at 3:45pm ET
- H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 8:30am ET
Live webcasts of these events will be available on the company's website under the 'Events and Presentations' section. The recordings will remain accessible for 90 days after each event, providing investors with extended access to Amylyx's presentations and discussions.
Amylyx Pharmaceuticals (Nasdaq: AMLX) has published exploratory analyses from the Phase 2 PEGASUS trial, showing encouraging effects of AMX0035 on cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) patients. The study, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, suggests that AMX0035 engages multiple pathological pathways related to neurodegeneration.
Key findings include:
- Reduced levels of p-tau181 and total tau compared to placebo
- Decreased levels of synaptic and neuronal degeneration biomarkers (neurogranin and FABP3)
- Reduced levels of YKL-40, a biomarker associated with cortical volume loss and cognitive decline
These results support the potential of AMX0035 in treating neurodegenerative diseases associated with tau dysfunction, including progressive supranuclear palsy (PSP), for which the ORION trial is ongoing.
Amylyx Pharmaceuticals (Nasdaq: AMLX) reported Q2 2024 financial results.
The company expanded its pipeline with avexitide, a Phase 3-ready GLP-1 receptor antagonist expected to enter Phase 3 in Q1 2025 for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism.
Updated Phase 2 HELIOS trial data for AMX0035 in Wolfram syndrome will be presented at ISPAD 2024.
Amylyx plans a multiple ascending dose trial of AMX0114 for ALS in H2 2024 and expects interim data for AMX0035 in progressive supranuclear palsy by mid-2025.
Financially, Q2 net product revenue was $(1.0) million due to adjustments, down from $98.2 million in Q2 2023. Cost of sales rose to $7.4 million. R&D expenses decreased to $23.3 million, SG&A expenses fell to $21.6 million, but restructuring expenses reached $22.9 million. Amylyx posted a net loss of $72.7 million, compared to a net income of $22.1 million in Q2 2023.
Cash and equivalents were $309.8 million, projecting a runway into 2026.
Amylyx Pharmaceuticals (Nasdaq: AMLX) has announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024. The company's senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and provide company updates. Investors and interested parties can access the call by dialing +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international). A live audio webcast will also be available on the company's website under the Investor section. The webcast will be archived and available for replay for 90 days following the event.
Amylyx Pharmaceuticals (NASDAQ: AMLX) has received Orphan Drug Designation from the European Commission for AMX0035 to treat Wolfram syndrome. This follows a similar designation by the FDA in 2020. Wolfram syndrome is a rare, progressive disease characterized by childhood-onset diabetes and neurodegeneration, with no approved treatments. Interim data from the Phase 2 HELIOS trial showed AMX0035 improved pancreatic function and glycemic control in 8 participants at Week 24. The drug was generally well-tolerated, with patients reporting disease improvement or stabilization. Topline data for all 12 participants is expected in fall 2024.
Amylyx Pharmaceuticals has acquired avexitide, a first-in-class GLP-1 receptor antagonist, from Eiger BioPharmaceuticals for $35.1 million. Avexitide is designed to treat hyperinsulinemic hypoglycemia and has received FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). The Phase 3 trial for PBH is set to begin in Q1 2025, with results expected in 2026. Two Phase 2 trials demonstrated significant reductions in hypoglycemic events, and avexitide showed a favorable safety profile. Amylyx will incorporate avexitide into its existing pipeline, bolstering its focus on treating endocrine and neuroscience disorders.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced that it will host a conference call and webcast on Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss its acquisition of avexitide from Eiger BioPharmaceuticals.
The conference call can be accessed by dialing +1 (800) 836-8184 in the U.S. and Canada or +1 (646) 357-8785 internationally, 10 minutes before the start time, and by asking to join the Amylyx Pharmaceuticals call.
A live audio webcast will be available in the Investor section of the Amylyx website and can be replayed for 90 days post-event.
Amylyx Pharmaceuticals (Nasdaq: AMLX) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. The event is in-person in Miami, Florida. Amylyx's management will present a fireside chat on June 11, 2024, at 8:00 AM EDT. Investors can access a live webcast of the presentation on the company's website, and it will be available for replay for 90 days.
Amylyx Pharmaceuticals reported financial results for the first quarter of 2024, highlighting progress in clinical trials for AMX0035 in Wolfram syndrome and PSP, along with plans to initiate a clinical trial of AMX0114 in ALS. The company announced intention to remove RELYVRIO/ALBRIOZA from the market based on Phase 3 trial results. Interim data from the HELIOS trial showed promising results in participants with Wolfram syndrome, and ORION study data is expected in mid-2025.
Financially, net product revenue increased, but the company incurred significant costs associated with discontinuing RELYVRIO/ALBRIOZA. Research and development expenses and SG&A expenses also increased, resulting in a net loss for the quarter. Despite this, the company maintains a strong cash position, providing expected cash runway into 2026.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will be participating in the 2024 Bank of America Health Care Conference with its Co-CEOs and Chief Medical Officer. The conference will feature a fireside chat on May 15, 2024, in Las Vegas. The presentation will be available via live webcast on the company's investor section for 90 days post-event.